title: [Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience].
authors.affiliation: Poliklinik für Rheumatologie, Universitätsklinikum Schleswig-Holstein, Campus Lübeck und Rheumaklinik Bad Bramstedt, Ratzeburger Allee 160, 23538 Lübeck, Germany. ahmadi@rheuma-zentrum.de
authors.forename: K
authors.initials: K
authors.lastname: Ahmadi-Simab
authors.forename: P
authors.initials: P
authors.lastname: Lamprecht
authors.forename: B
authors.initials: B
authors.lastname: Hellmisch
authors.forename: W L
authors.initials: WL
authors.lastname: Gross
mesh_terms: D000284:Administration, Oral; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000077300:Bosentan; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D065128:Endothelin Receptor Antagonists; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D010807:Physical Endurance / Q000187:drug effects; D010865:Pilot Projects; D016032:Randomized Controlled Trials as Topic; D012595:Scleroderma, Systemic / Q000188:drug therapy*; D013449:Sulfonamides / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D013449:Sulfonamides; D000077300:Bosentan